Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP]) or are localized, typically on the hands and feet (palmoplantar pustular psoriasis [PPP]). Despite being more severe than general plaque psoriasis and potentially life-threatening, no drugs have been well studied for this psoriasis subtype and none are specifically indicated for PPP / GPP. Treatment typically includes topical corticosteroids, methotrexate, retinoids, and phototherapy. However, biologics, including TNF-alpha inhibitors and IL-17 inhibitors, and targeted orals used for plaque psoriasis are also increasingly being used to treat PPP / GPP.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PPP / GPP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PPP / GPP patients?
  • How have TNF-alpha inhibitors been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of PPP / GPP patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of PPP / GPP patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Palmoplantar Pustular Psoriasis/Generalized Pustular Psoriasis (US )
    • Treatment Algorithms CDA Palmoplantar Pustular Psoriasis Generalized Pustular Psoriasis US October 2019

Author(s): Colleen E. Albacker, PhD

Colleen E. Albacker, is a director with the Immune and Inflammatory Disorders group at Decision Resources Group, where she comanages a team of analysts generating syndicated market research content. She has authored market research reports analyzing physician, payer, and market trends in respiratory indications, including asthma and COPD. Prior to joining Decision Resources Group, Dr. Albacker conducted her graduate research on chromatin-modifying factors in zebrafish cancer and hematopoietic development at Harvard Medical School and Boston Children’s Hospital. She also gained experience with market research through a fellowship with the Harvard Office of Technology Development. Dr. Albacker holds a in genetics from Harvard University and a in biology with honors from the Pennsylvania State University.

Related Reports

Psoriasis | Emerging Therapies | Skyrizi Launch Tracking Wave 2 (US)

This report is available to find out more click the link and fill out the form to get more details.

View Details

Psoriasis | Landscape & Forecast | Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-a...

View Details

Psoriasis | Access and Reimbursement | US | 2018

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (

View Details

Psoriasis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbr...

View Details